We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EA icon
201
Electronic Arts
EA
$52.4B
$326K ﹤0.01%
2,270
– –
ANSS
202
DELISTED
Ansys
ANSS
$312K ﹤0.01%
900
– –
MKTX icon
203
MarketAxess Holdings
MKTX
$4.15B
$307K ﹤0.01%
662
– –
VRSK icon
204
Verisk Analytics
VRSK
$26.4B
$304K ﹤0.01%
1,739
– –
OLED icon
205
Universal Display
OLED
$3.71B
$303K ﹤0.01%
1,365
– –
SPOT icon
206
Spotify
SPOT
$99.2B
$303K ﹤0.01%
+1,100
New +$279K
CTLT
207
DELISTED
CATALENT, INC.
CTLT
$292K ﹤0.01%
2,700
– –
CSGP icon
208
CoStar Group
CSGP
$11.3B
$290K ﹤0.01%
3,500
– –
STNE icon
209
StoneCo
STNE
$2.62B
$288K ﹤0.01%
4,300
– –
JD icon
210
JD.com
JD
$40.8B
$287K ﹤0.01%
3,600
– –
IPGP icon
211
IPG Photonics
IPGP
$3.89B
$285K ﹤0.01%
1,350
– –
CYBR
212
DELISTED
CyberArk
CYBR
$274K ﹤0.01%
2,100
– –
MELI icon
213
Mercado Libre
MELI
$91.3B
$265K ﹤0.01%
170
– –
CVAC
214
CALL
DELISTED
CureVac
CVAC
$39K ﹤0.01%
+70
New +$7K
ASND icon
215
Ascendis Pharma A/S
ASND
$16.7B
– –
-15,500
Closed -$2M
CAH icon
216
Cardinal Health
CAH
$53.4B
– –
-24,000
Closed -$1.46M
CVAC
217
DELISTED
CureVac
CVAC
– –
-28,900
Closed -$2.89M
DVA icon
218
DaVita
DVA
$15.1B
– –
-367,600
Closed -$39.6M
KYNB
219
Kyntra Bio
KYNB
$28.5M
– –
-2,400
Closed -$2.08M
IRTC icon
220
iRhythm Holdings
IRTC
$3.59B
– –
-87,631
Closed -$12.2M
PAYX icon
221
Paychex
PAYX
$40.4B
– –
-3,900
Closed -$382K
QURE icon
222
uniQure
QURE
$2.68B
– –
-34,500
Closed -$1.16M
SRPT icon
223
Sarepta Therapeutics
SRPT
$1.66B
– –
-20,300
Closed -$1.51M
VYGR icon
224
Voyager Therapeutics
VYGR
$187M
– –
-31,800
Closed -$150K
YI
225
111 Inc
YI
– –
-8,500
Closed -$1.17M
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.